09:51 AM EST, 12/23/2024 (MT Newswires) -- Zura Bio ( ZURA ) said Monday that it has begun a phase 2 study evaluating tibulizumab as a treatment for adult patients with systemic sclerosis.

The immunology company said the study includes a 24-week efficacy period and a 28-week open-label extension. It also said the primary endpoint of the trial is the modified Rodnan Skin Score.

Shares of Zura Bio ( ZURA ) were down 1.8% in recent trading.

Price: 2.24, Change: -0.04, Percent Change: -1.75